Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease
- Conditions
- refractory uveitis of Behcet's disease
- Registration Number
- JPRN-UMIN000025451
- Lead Sponsor
- Yokohama City University Hospital
- Brief Summary
The duration of infliximab for the 3 cases was an average of 7 years and 8 months, and the remission of ocular inflammation after introduction of infliximab was an average of 6 years and 8 months. In all cases, there was no eye inflammation attack for 1 year, the eye activity score remained at 0, and there were no cases of reintroduction of infliximab. However, all cases had relapsed systemic symptoms such as extraocular symptoms such as folliculitis,recurrent oral aphthae, and unknown fever.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3
Not provided
1. Patients with kidney dysfunction 2. Patients with liver dysfunction 3. Patients with pancreatic dysfunction 4. Hypertension patients 5. Patients with infection 6. Patients with malignant tumors (such as malignant lymphoma) or a previous medical history 7. Patients during ultraviolet radiation therapy including PUVA therapy 8. Elderly (65 years and over) 9. Hepatitis B virus carrier, patient with hepatitis C virus carrier 10. Patients who are using contraindicated drugs in combination with cyclosporine,Living vaccine (dry live attenuated measles vaccine, dry live attenuated feline vaccine, oral raw polio vaccine, dry raw BCG, etc.), tacrolimus excluding external medicine (prograf), pitavastatin ), Rosuvastatin (crestor), bosentan (trakuria), aliskiren (radiolith), asnaprevir (sunbella), baniprevir (bani hep) 11. Other patients judged inappropriate by the research doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method